Privosegtor Receives Breakthrough Drug Designation
In a phase 2 trial, the drug showed functional and structural signals in optic neuritis.
-
By
-
Conexiant News Staff
-
January 6, 2026
-
Clinical Scorecard: Privosegtor Receives Breakthrough Drug Designation
At a Glance
| Category | Detail |
|---|
| Condition | Optic Neuritis |
| Key Mechanisms | Neuroprotective therapy targeting optic neuropathies |
| Target Population | Patients with acute optic neuritis |
| Care Setting | Clinical trials and neuro-ophthalmic care |
Key Highlights
- Privosegtor received FDA breakthrough therapy designation.
- Phase 2 ACUITY trial showed significant visual acuity improvement.
- Combination therapy with methylprednisolone demonstrated structural preservation of retinal and optic nerve.
- Common adverse events included headache and acne; no serious events reported.
- PIONEER program initiated for further pivotal trials.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of optic neuritis based on clinical evaluation and imaging.
Management
- Privosegtor at 3 mg/kg/day in combination with intravenous methylprednisolone.
Monitoring & Follow-up
- Monitor visual acuity and retinal structure during treatment.
Risks
- Potential for headache and acne as common adverse events.
Patient & Prescribing Data
Patients with acute optic neuritis
Privosegtor shows promise in improving visual outcomes and preserving optic nerve integrity.
Clinical Best Practices
- Consider combination therapy with methylprednisolone for enhanced efficacy.
- Regularly assess visual acuity and retinal health in treated patients.
References
